[Editorial] Tackling key immunological and immuno-dermatological pathways and their link to treatment options

Abstract

[...]they generate substantial healthcare costs. [...]the objectives in NAFLD and NASH therapy are to reduce disease activity, to attenuate the progression of fibrosis and to reduce the risk factors. Several conditions are of critical value in influencing the outcome of pregnancies as well as the wellbeing of the fetus. [...]Voicu et al (14) postulated in ‘Maternal inherited thrombophilia and pregnancy outcomes’ that maternal thrombophilia may be a risk factor for preeclampsia and intrauterine growth retardation. [...]they studied 459 pregnant women and demonstrated that the type of thrombophilic mutation most commonly found was the MTHFR mutation (25.7%), followed by the prothrombin gene mutation (20.9%) and the Leiden factor V mutation (15.7%). In their original study entitled ‘Prognosis of autoimmune thyroid disease associated with hereditary thrombophilia during pregnancy’, Păuleț et al (17) assessed the connection between acute and chronic thyroiditis and inherited thrombophilia and their potential implications in pregnancy. Besides the well-accounted impact of hereditary thrombophilia during pregnancy, which is emphasized in their research by the incidence of moderate preeclampsia, they also account for a direct and statistically significant relationship between thrombophilia and moderate intensity autoimmune diseases (including autoimmune thyroiditis).